[The value of radiotherapy in the treatment of esthesioneuroblastoma].
Three cases of aesthesioneuroblastoma highlight the problems of treatment of these extremely rare tumours. These tumours of the olfactory epithelium arise in the nasal cavity and invade the paranasal sinuses, the orbit and the skull base. As symptoms occur late in the disease, most cases are advanced when diagnosed. Early cases can be treated by surgery, by irradiation or by a combination of, but the local control rate is about 60% regardless of the treatment. Chemotherapy should be used in addition to operation and irradiation, especially in advanced cases with nodal and distant metastases. An irradiation dose of 40-60 Gy is recommended. CT-aided treatment planning, sophisticated irradiation techniques, the use of high-energy photons and reliable immobilization measures are indispensable. A 5-year survival rate for all stages of 50% is reported. The recurrence rate in advanced stages is high, so that the benefits and risks of the different, combined treatment modalities must be evaluated carefully.
Feyerabend
T
T
Klinik und Poliklinik für Strahlentherapie, Würzburg.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000532:radiotherapy* / Q000601:surgery; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000532:radiotherapy* / Q000601:surgery; D009669:Nose Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D010255:Paranasal Sinus Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D011879:Radiotherapy Dosage
Die Stellung der Radiotherapie in der Behandlung des Asthesioneuroblastoms.